Notable Labs

Notable Labs

Notable Labs is a company providing personalized drug combination testing service for cancer patients.

Notable Labs assists doctors in identifying personalized combinations of FDA-approved treatments for cancer patients. Notable is focused on individual patients and using existing treatments, they are exploring new indications of drugs and identifying mechanisms underlying cancer progression and drug resistance. Using robotic and modern data science, Notable is developing a scalable, iterative model that will turn individual treatment selection into a quantifiable problem.

Notable has formed several clinical trial partnerships with health centers and hospitals, including but not limited to:

  • The University of Kansas Medical Center
  • Orlando Health
  • UHN Princess Margret Cancer Centre
  • The University of Texas, MD Anderson Cancer Center
  • UCSF Hellen Diller Family Comprehensive Cancer Center

Notable has published numerous cancer research studies with various organizations, many of which have been made available for public reading.

Timeline

June 9, 2020

Notable's The ANSWer Study

April 30, 2020

Notable and MDS Foundation Announce Partnership on Clinical MDS Trials and Drug Therapies for MDS Patients

April 9, 2020

Notable, announces its board has appointed life science executive, Laurie Heilmann, as Chief Executive Officer.

January 22, 2020

Notable Labs launches rolling blood cancer trial to test its AI system

July 16, 2019

Notable Labs has a post-money valuation in the range of $100M to $500M as of Jul 16, 2019 according to PrivCo.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Notable Series B round, July 2019
40,000,000
July 2019
7 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Hiroomi Tada, M.D., Ph.D.

Cheif Medical Officer

Kathryn Vanderlaag

Senior Director, Biology and Assay Development

Laurie Heilmann

CEO

Marianne Santaguida, Ph.D.

VP of Partnerships

Matt De Silva

Founder & Executive Chairman

Michael Horowitz

COO & General Counsel

Peter Quinzio

Founder

Robbie Narang

VP of Operations

Scott Patterson

VP of Engineering

Further reading

Title
Author
Link
Type
Date

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study

Jenny L. Smith, Rhonda E. Ries, Tiffany Hylkema, Todd A Alonzo, Robert B Gerbing, Marianne T. Santaguida, Lisa Eidenschink Brodersen, Laura Pardo, Carrie L Cummings, Keith R Loeb, Quy Le, Suzan Imren, Amanda R Leonti, Alan S. Gamis, Richard Aplenc, E Anders Kolb, Jason E. Farrar, Timothy J. Triche, Cu Nguyen, Daoud Meerzaman, Michael R Loken, Vivian G. Oehler, Hamid Bolouri and Soheil Meshinchi

Web

Notable Labs lands $40M to expand AI-based cancer treatment tech

Amirah Al Idrus

Web

July 16, 2019

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.